EVRYSDI is a survival of motor neuron 2 (SMN2) splicing modifier indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Health care professionals are asked to report any suspected adverse reactions at
This information is intended for HCP only. This is a prescription based drug. Please consult your doctor if you need more information.